Dr. Marshall P. Stagg
Claim this profileOur Lady of the Lake Physicians Group - Medical Oncology
Expert in Cancer
Studies Lung Cancer
36 reported clinical trials
79 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Stage II
Stage I
Stage IV
Affiliated Hospitals
Clinical Trials Marshall P. Stagg is currently running
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Recruiting1 award Phase 2 & 310 criteria
Genetic Testing
for Early-Stage Lung Cancer
This study is evaluating whether genetic testing may help determine the best treatment for patients with lung cancer.
Recruiting0 awards N/A4 criteria
More about Marshall P. Stagg
Clinical Trial Related4 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 19 Active Clinical TrialsTreatments Marshall P. Stagg has experience with
- Nivolumab
- Atezolizumab
- Carboplatin
- Paclitaxel
- Cisplatin
- Fluorouracil
Breakdown of trials Marshall P. Stagg has run
Cancer
Lung Cancer
Colorectal Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marshall P. Stagg specialize in?
Marshall P. Stagg focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Marshall P. Stagg currently recruiting for clinical trials?
Yes, Marshall P. Stagg is currently recruiting for 18 clinical trials in Baton Rouge Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Marshall P. Stagg has studied deeply?
Yes, Marshall P. Stagg has studied treatments such as Nivolumab, Atezolizumab, Carboplatin.
What is the best way to schedule an appointment with Marshall P. Stagg?
Apply for one of the trials that Marshall P. Stagg is conducting.
What is the office address of Marshall P. Stagg?
The office of Marshall P. Stagg is located at: Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana 70809 United States. This is the address for their practice at the Our Lady of the Lake Physicians Group - Medical Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.